Leslie Spikes, MD
Internal Medicine · Kansas City, KSNPI 1528289832
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,320 of the $6,879 with a category attached, or 77.3%. United Therapeutics Corporation accounts for 93.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $6,556 and has fallen 95.1% since, to $320 in 2022. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $382.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$6K
- Merck$320
- Actelion Pharmaceuticals US, Inc.$125
Across 188 payments — averaging $24,062 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.9M
- United Therapeutics Corporation$271K
- Insmed, Inc.$108K
- Novartis$70K
- Acceleron Pharma, Inc.$47K
- Sumitomo Pharma America, Inc.$46K
- plus $58K from 3 others
What the payments were for
- Consulting fees$5,32077%
- Travel & lodging$1,31019%
- Food & beverage$2313%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 16 | $6,434 |
| Merck | 1 | $320 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,879 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 303 | $3,808,564 |
| Tyvaso DpiTreprostinil | 106 | $2,522,412 |
| WinrevairSotatercept-Csrk | 83 | $1,501,809 |
| AdempasRiociguat | 64 | $885,947 |
| UptraviSelexipag | 35 | $883,039 |
| RemodulinTreprostinil Sodium | 11 | $401,935 |
| OfevNintedanib Esylate | 13 | $158,675 |
| Tadalafil | 247 | $137,630 |
| Ambrisentan | 36 | $62,253 |
| Sildenafil Citrate | 123 | $32,057 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $20,648 |
| XareltoRivaroxaban | 18 | $16,325 |
| EliquisApixaban | 26 | $15,405 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,015 |
| Midodrine Hcl | 12 | $3,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $125 | $4,691,603338 claims |
| MerckWinrevair | $320 | $1,501,80983 claims |
| United Therapeutics CorporationRemodulin | $6,434 | $401,93511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Kansas City
- Shadi HamdehKansas City$959K
- Lucas PittsKansas City$235K
- Mark HamblinKansas City$147K
- Aaron RohrKansas City$54K
- Alanna LeeKansas City$4K
- Donna GriebelLawrence$781K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.